CRISPR Therapeutics AG (NASDAQ: CRSP) on Friday, soared 3.43% from the previous trading day, before settling in for the closing price of $46.29. Within the past 52 weeks, CRSP’s price has moved between $43.42 and $91.10.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 33402.13%. The company achieved an average annual earnings per share of -168.09%. With a float of $81.67 million, this company’s outstanding shares have now reached $85.35 million.
Let’s determine the extent of company efficiency that accounts for 407 employees. In terms of profitability, gross margin is 30.6%, operating margin of -164.86%, and the pretax margin is -117.29%.
CRISPR Therapeutics AG (CRSP) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of CRISPR Therapeutics AG is 4.31%, while institutional ownership is 67.65%. The most recent insider transaction that took place on Nov 11 ’24, was worth 1,668,678. In this transaction Chief Executive Officer of this company sold 30,000 shares at a rate of $55.62, taking the stock ownership to the 196,540 shares. Before that another transaction happened on Oct 14 ’24, when Company’s General Counsel and Secretary sold 1,089 for $46.28, making the entire transaction worth $50,399. This insider now owns 62,597 shares in total.
CRISPR Therapeutics AG (CRSP) Recent Fiscal highlights
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported 1.1 earnings per share (EPS) for the period topping the consensus outlook (set at 0.05) by 1.05. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.38 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -168.09% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -3.70% during the next five years compared to 10.83% growth over the previous five years of trading.
CRISPR Therapeutics AG (NASDAQ: CRSP) Trading Performance Indicators
CRISPR Therapeutics AG (CRSP) is currently performing well based on its current performance indicators. A quick ratio of 21.64 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 20.84.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.82, a number that is poised to hit -1.25 in the next quarter and is forecasted to reach -5.00 in one year’s time.
Technical Analysis of CRISPR Therapeutics AG (CRSP)
Looking closely at CRISPR Therapeutics AG (NASDAQ: CRSP), its last 5-days average volume was 1.82 million, which is a jump from its year-to-date volume of 1.49 million. As of the previous 9 days, the stock’s Stochastic %D was 13.74%. Additionally, its Average True Range was 2.32.
During the past 100 days, CRISPR Therapeutics AG’s (CRSP) raw stochastic average was set at 22.01%, which indicates a significant increase from 17.48% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 53.62% in the past 14 days, which was higher than the 48.32% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $47.98, while its 200-day Moving Average is $57.05. However, in the short run, CRISPR Therapeutics AG’s stock first resistance to watch stands at $48.64. Second resistance stands at $49.39. The third major resistance level sits at $50.79. If the price goes on to break the first support level at $46.49, it is likely to go to the next support level at $45.09. Now, if the price goes above the second support level, the third support stands at $44.34.
CRISPR Therapeutics AG (NASDAQ: CRSP) Key Stats
Market capitalization of the company is 4.23 billion based on 85,353K outstanding shares. Right now, sales total 371,210 K and income totals -153,610 K. The company made 600 K in profit during its latest quarter, and -85,940 K in sales during its previous quarter.
